Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study

doi:10.4239/wjd.v9.i10.165

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9031)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

429

WORD

250

HTML

4158

Tables (1-3)

236

Sum=5073

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

442

Download

900

Sum=1342

Publishing Process of This Article

Item

Count

Browse

1083

Download

1533

Sum=2616

Oct 15, 2018 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Diabetes. Oct 15, 2018; 9(10): 165-171
Published online Oct 15, 2018. doi: 10.4239/wjd.v9.i10.165

Table 1 Subject characteristics at baseline

	Anagliptin	Linagliptin	P-value
Age (yr)	63.5 (12.9)	62.7 (11.9)	0.63
Men/women	74/43	75/42	0.89
Height (cm)	162.1 (10.4)	162.5 (9.1)	0.77
Weight (kg)	64.4 (16.1)	66.1 (14.7)	0.39
BMI (kg/m²)	24.3 (4.7)	24.9 (4.3)	0.23
Duration of diabetes (yr)	11.9 (8.6)	10.5 (8.5)	0.21
History of CVD (yes/no)	36/81	32/85	0.56
Smoking habit (yes/no)	44/73	46/71	0.79
Drinking habit (yes/no)	65/52	62/55	0.75
SBP (mmHg)	130.4 (18.4)	128.5 (18.7)	0.43
DBP (mmHg)	72.9 (14)	72.9 (11.4)	0.99
AST (U/L)	21.9 (9.3)	29.8 (26.7)	0.029
ALT (U/L)	24.9 (15)	33.1 (35.1)	0.069
Cr (mg/dL)	0.71 (0.19)	0.79 (0.32)	0.03
PG (mmol/L)	10.71 (4.49)	12.06 (5.25)	0.036
HbA1c (mmol/L)	11.1 (2.8)	12 (3.3)	0.053
T-C (mmol/L)	5.3 (0.88)	5.48 (1.02)	0.17
TG (mmol/L)	1.63 (1.17)	2.07 (1.5)	0.009
HDL-C (mmol/L)	1.36 (0.34)	1.33 (0.37)	0.55
LDL-C (mmol/L)	3.19 (0.8)	3.19 (0.88)	0.95
UACR (mg/gCr)	50.60 (78.4)	47.6 (92)	0.65

BMI: Body mass index; CVD: Cardiovascular disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AST: Aspartate transaminase; ALT: Alanine aminotransferase; Cr: Creatinine; PG: Plasma glucose; HbA1c: Hemoglobin A1c; T-C: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; UACR: Urinary albumin creatinine ratio.

Table 2 Medications in study subjects

	Anagliptin	Linagliptin	P-value
Dosage	100 mg: 47; 200 mg: 70	5 mg	-
Anti-hypertensive agents	42	46	0.59
ARB or ACE inhibitors	31	36	0.47
Cholesterol-lowering agents	41	37	0.58
Insulin	7	8	0.79
Concomitant oral hypoglycemic agents
Metformin	48	42	0.42
Sulfonylureas	44	40	0.59
Glinides	3	4	0.70
α-glucosidase inhibitors	4	6	0.52
Pioglitazone	1	2	0.56
SGLT2 inhibitors	1	0	0.32
No medication	33	37	0.57
Additional medications for hypertension	1	2	0.56
Additional medications for dyslipidemia	3	3	1.00
Additional medications for diabetes	12	16	0.42

ARB: Angiotensin II receptor blocker; ACE: Angiotensin converting enzyme; SGLT2: Sodium-glucose cotransporter 2.

Table 3 Changes in clinical parameters after starting the dipeptidyl peptidase-4 inhibitors therapy

	Anagliptin				Linagliptin
	3 mo	6 mo	12 mo	24 mo	3 mo	6 mo	12 mo	24 mo
Weight (kg)	64.5 (16.2)	65.4 (15.7)	64.7 (15.5)	63.7 (16.4)	66.1 (15.1)	66 (16.9)	67.3 (14.2)	66.4 (14.8)
SBP (mmHg)	128.6 (17.2)	128.2 (14.8)	126.8 (16.6)	130.1 (16.6)	129.3 (17.7)	127.1 (16.4)	128.9 (19.1)	124.9 (16)
DBP (mmHg)	70.7 (11.4)	70.9 (9.9)	69.4 (12.1)	69.1 (9.5)^b	70.7 (11.4)	69.3 (10.8)	72.5 (11.2)	70.2 (8.6)
AST (U/L)	22.5 (9.6)	22.4 (8.8)	22.3 (10)	23.8 (12.3)	22.7 (12.7)	24.9 (17.1)	23.2 (13.1)	23.7 (12.4)
ALT (U/L)	23 (14.9)^b	23 (14.8)^a	22.6 (15.7)^b	25.5 (18)	23.5 (12.9)	24.8 (14.8)	24 (13.9)	23.7 (15.4)
Cr (mg/dL)	0.74 (0.18)	0.77 (0.2)	0.77 (0.21)	0.77 (0.2)	0.85 (0.33)	0.86 (0.4)	0.9 (0.5)	0.84 (0.38)^d
PG (mmol/L)	8.96 (3.4)^a	8.8 (2.9)	8.91 (3.16)	9.12 (4.19)^b	9.54 (3.82)^d	9.28 (3.85)^d	9.48 (3.28)^d	9.51 (3.5)^b
HbA1c (mmol/L)	9.3 (2.3)^d	9.4 (2.1)^d	9.3 (1.8)^b	9.7 (1.9)^b	9.3 (2)^b	9.1 (1.8)^d	9.6 (2.2)^d	9.2 (1.8)^d
T-C (mmol/L)	5.11 (0.87)	5.11 (0.78)^b	5.19 (0.69)	5.03 (0.64)	5.11 (0.86)	5.14 (0.89)	5.31 (0.97)	5.09 (0.81)
TG (mmol/L)	1.83 (2.05)	1.73 (1.71)	1.64 (0.92)	1.51 (0.83)	2.1 (1.74)	1.85 (1.23)	2.11 (1.83)	1.76 (1.19)
HDL-C (mmol/L)	1.32 (0.3)	1.31 (0.32)	1.29 (0.27)	1.4 (0.37)	1.31 (0.37)	1.35 (0.42)	1.31 (0.34)	1.39 (0.38)^a
LDL-C (mmol/L)	3 (0.8)	3.07 (0.78)	3.13 (0.7)	2.96 (0.53)	2.85 (0.86)	2.94 (0.83)	3.04 (0.86)	2.91 (0.75)
UACR (mg/gCr)	40.7 (76.8)	-	-	-	23.8 (34.9)	-	-	-

Superscripts indicate statistically significant changes from baseline:

^aP < 0.05;

^bP < 0.01;

^dP < 0.001.

SBP: Systolic blood pressure; DBP: Diastolic blood pressure; AST: Aspartate transaminase; ALT: Alanine aminotransferase; Cr: Creatinine; PG: Plasma glucose; HbA1c: Hemoglobin A1c; T-C: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; UACR: Urinary albumin creatinine ratio.

Citation: Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171
URL: https://www.wjgnet.com/1948-9358/full/v9/i10/165.htm
DOI: https://dx.doi.org/10.4239/wjd.v9.i10.165